<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02238496</url>
  </required_header>
  <id_info>
    <org_study_id>AAAM3801</org_study_id>
    <nct_id>NCT02238496</nct_id>
  </id_info>
  <brief_title>Perifosine and Torisel (Temsirolimus) for Recurrent/Progressive Malignant Gliomas</brief_title>
  <official_title>Pilot Trial of Temsirolimus and Perifosine in Recurrent/Progressive Malignant Gliomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Andrew Lassman</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>AEterna Zentaris</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Columbia University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test the effectiveness of a drug called temsirolimus in
      combination with a drug called perifosine in treating brain tumors that have continued to
      grow after previous treatment. Temsirolimus is an intravenous drug approved by the FDA for
      treatment of other cancers (kidney cancer, certain types of lymphoma) but not for brain
      tumors. Perifosine is a pill that has not been approved by the FDA which blocks a messenger
      that tells cancer cells to grow. Research suggests that combined treatment with both drugs is
      better than either alone, and that it is reasonably safe.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Malignant gliomas are the most common primary brain tumors, and glioblastoma (GBM) is the
      most common subtype in adults, representing more than 50% of gliomas. Standard initial
      treatment for newly diagnosed GBM consists of maximal surgical resection followed by
      radiotherapy to the tumor bed and chemotherapy with an oral DNA alkylator, temozolomide.
      However, recurrence is nearly universal despite standard therapy. There is no standard
      treatment at recurrence. Median survival is about 15 months from diagnosis and 6 months from
      recurrence. Once patients develop tumor progression, conventional chemotherapy is generally
      ineffective.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in tumor size</measure>
    <time_frame>Every 8 weeks, starting at 8 weeks after Day 1 of treatment, and up to 48 months</time_frame>
    <description>Tumor measurements will be calculated and compared to baseline measurements to determine if the regimen induces radiographic response (tumor shrinkage or stabilization) and/or delay in disease progression. These statuses will be categorized as Complete Response (CR), Partial Response (PR), Minor Response (MR), Stable Disease (SD), Progressive Disease (PD), and Unknown (UNK).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in tumor size specifically at 6 months</measure>
    <time_frame>Up to 6 months from drug administration</time_frame>
    <description>Subjects' disease status will be evaluated for progression at 6 months: 6 months from first day of study drug administration (Arm A) and 6 months from first day of study drug administration following surgery (Arm B). This will be accomplished via radiographic measurement comparisons between follow-up on-study scans, compared to the baseline scan tumor measurements.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Overall Survival Rate</measure>
    <time_frame>From time of first study drug administration until expiration, (approximately 48 months)</time_frame>
    <description>Overall survival will be calculated by using the interval between the date in which the first study drug administration took place (Arm A), and first day of study drug administration following surgery (Arm B), until the date of subject expiration.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Brain Tumor, Recurrent</condition>
  <condition>Glioblastoma</condition>
  <condition>Anaplastic Astrocytoma</condition>
  <condition>Anaplastic Oligodendroglioma</condition>
  <condition>Mixed Glioma</condition>
  <arm_group>
    <arm_group_label>ARM B</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Cytoreductive surgery planned (surgical cohort). After post-operative standard evaluations, patients will resume therapy. After anti-emetic prophylaxis, patients will receive the first divided dose of the perifosine loading dose after recovery from surgery. Patients will be observed for at least 30 minutes to ensure there has been adequate anti-emetic prophylaxis, and then patients will receive temsirolimus administered over 30-60 minutes IV. The remaining divided doses of the perifosine loading dose will then be administered. Patients will then return weekly for infusion of temsirolimus over 30-60 minutes IV. Dosing will be continuous although for the purposes of evaluation, a cycle will be defined as 4 weeks (28 days).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ARM A</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>No-Cytoreductive surgery planned (medical cohort). After anti-emetic prophylaxis, patients will receive the first divided dose of the perifosine loading dose. Patients will be observed for at least 30 minutes to ensure there has been adequate anti-emetic prophylaxis, and then patients will receive temsirolimus administered over 30-60 minutes IV. The remaining divided doses of the perifosine loading dose will then be administered. Patients will then return weekly for infusion of temsirolimus over 30-60 minutes IV. Dosing will be continuous although for the purposes of evaluation, a cycle will be defined as 4 weeks (28 days).</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cytoreductive surgery</intervention_name>
    <description>Standard of care/routine cytoreductive glioma resection surgery. Arm B only.</description>
    <arm_group_label>ARM B</arm_group_label>
    <other_name>Resection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Perifosine</intervention_name>
    <description>Perifosine is a pill that has not been approved by the FDA which blocks a messenger that tells cancer cells to grow.</description>
    <arm_group_label>ARM B</arm_group_label>
    <arm_group_label>ARM A</arm_group_label>
    <other_name>AEZS-104/D-21266</other_name>
    <other_name>KRX-0401</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temsirolimus</intervention_name>
    <description>Temsirolimus is an intravenous drug approved by the FDA for treatment of other cancers (kidney cancer, certain types of lymphoma) but not for brain tumors.</description>
    <arm_group_label>ARM B</arm_group_label>
    <arm_group_label>ARM A</arm_group_label>
    <other_name>Torisel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed intracranial glioblastoma (GBM), including sub variants

          -  At least 15 unstained slides or at least 1 tissue blocks must be collected from at
             least one prior surgery.

          -  Received prior radiotherapy and prior temozolomide as treatment for the malignant
             glioma

          -  Recovered from toxic effects of prior therapies and at least 2 weeks must have elapsed
             since any prior signaling pathway modulators; in general, at least 4 weeks must have
             elapsed from any other anticancer therapy

          -  Able to undergo contrast enhanced magnetic resonance imaging (MRI) scans or CT scans

          -  Shown unequivocal evidence for contrast enhancing tumor progression by MRI or CT in
             comparison to a prior scan

          -  Age &gt; or = 18 years

          -  Karnofsky Performance Status &gt; or = 70

          -  Life expectancy of &gt; 8 weeks

          -  Normal organ and marrow function, adequate liver function, and adequate renal function
             before starting therapy

          -  Platelet count of at least 100,000/mm3 on at least 2 consecutive blood draws at least
             1 week apart with results stable or trending upward

          -  Normal coagulation

          -  Cholesterol level &lt; or = 350 mg/dl and triglycerides level &lt; or = 400 mg/dl

          -  Women of child-bearing potential and men must agree to use adequate contraception
             prior to study entry and for the duration of study participation

          -  Women of childbearing potential must have a negative beta-human chorionic gonadotropin
             (B-hCG) pregnancy test documented within 7 days prior to treatment

          -  Women must agree not to breast feed

          -  Ability to understand and the willingness to sign a written informed consent document

          -  Ability to swallow tablets

        Group A (medical) specific inclusion criteria:

          -  Fulfill all of the general inclusion criteria

          -  At least 3 months between any prior brain radiotherapy and initiation of study therapy

          -  MRI/CT must demonstrate measurable enhancing tumor of at least 1cm squared in
             cross-sectional area to allow assessment of radiographic response

          -  On stable or decreasing dose of corticosteroids for a minimum of 5 days before the
             baseline MRI/CT

          -  The baseline brain MRI/CT must be performed less than 15 days prior to initiation of
             study treatment. Otherwise it must be repeated

        Group B (surgical) specific inclusion criteria:

          -  Fulfill all of the general inclusion criteria

          -  Have cytoreductive surgery as part of their routine care for recurrent tumor

          -  Have cytoreductive surgery as part of their routine care for recurrent tumor

          -  A brain MRI/CT must be performed less than 15 days prior to initiation of study
             treatment. Otherwise it must be repeated

        Exclusion Criteria:

          -  There is no limit on the number or type of prior chemotherapies except:

               1. convection enhanced delivery, catheter based intra-tumoral treatment, or
                  carmustine (BCNU)/GliadelÂ® wafers

               2. stereotactic radiosurgery, or re-irradiation of any type

               3. agent designed to inhibit mTOR or PI3K/AKT

               4. direct Vascular Endothelial Growth Factor (VEGF)/Vascular Endothelial Growth
                  Factor Receptors (VEGFR) inhibitors

          -  Smoking or plan to smoke tobacco or marijuana during study therapy

          -  Plan to eat grapefruit or drink grapefruit juice during study therapy

          -  Receiving any other investigational agents concurrently with study treatment

          -  Taking hepatic Enzyme Inducing Anti-Epileptic Drug (EIAED)

          -  Taking medications that are inducers or inhibitors of Cytochrome P450 3A4 (CYP3A4) for
             at least two weeks prior to study treatment

          -  Uncontrolled intercurrent illness

          -  HIV-positive patients on combination antiretroviral therapy

          -  Other active concurrent malignancy

          -  History of gout which can be exacerbated by perifosine

          -  Known history of allergic reactions attributed to compounds of similar chemical or
             biologic composition to temsirolimus or perifosine

          -  Therapeutic anticoagulation

          -  History of hemorrhagic or ischemic stroke

          -  Prior intratumoral bleeding must be evaluated with a non-contrast head CT to exclude
             acute blood prior to start of treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew B Lassman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York City</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York City</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://hiccc.columbia.edu/clinicaltrials</url>
    <description>Herbert Irving Comprehensive Cancer Center (HICCC) Clinical Trials Page</description>
  </link>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 29, 2014</study_first_submitted>
  <study_first_submitted_qc>September 11, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2014</study_first_posted>
  <last_update_submitted>September 7, 2016</last_update_submitted>
  <last_update_submitted_qc>September 7, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 8, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Columbia University</investigator_affiliation>
    <investigator_full_name>Andrew Lassman</investigator_full_name>
    <investigator_title>John Harris Associate Professor of Neurology</investigator_title>
  </responsible_party>
  <keyword>Glioblastoma</keyword>
  <keyword>Anaplastic Astrocytoma</keyword>
  <keyword>Anaplastic Oligodendroglioma</keyword>
  <keyword>Mixed Glioma</keyword>
  <keyword>akt-Oncogene Protein</keyword>
  <keyword>mTOR Protein</keyword>
  <keyword>Glioma</keyword>
  <keyword>Brain Neoplasms</keyword>
  <keyword>Brain Tumor, Recurrent</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
    <mesh_term>Glioma</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
    <mesh_term>Astrocytoma</mesh_term>
    <mesh_term>Oligodendroglioma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

